The Named Patient Programme (NPP) allows patients with serious, rare, or life-threatening conditions to access medications that are not yet approved or commercially available in their country. This program provides an essential pathway for patients who have exhausted all other treatment options, enabling them to receive critical therapies on a case-by-case basis under the guidance of healthcare professionals. Karunesh BioSciences ensures timely and compliant access to these medicines, helping bridge the gap between cutting-edge treatments and patients in need.